Inhibition of HIV-1 replication in human primary cells by a dolabellane diterpene isolated from the marine algae Dictyota pfaffii

Planta Medica

Volumn 72, Issue 4, 2006, Pages 295-299

  Cirne Santos, Claudio Cesar ^a,b,c   Teixeira, Valéria L ^a   Castello Branco, Luiz Roberto ^c   Frugulhetti, Izabel C P P ^a   Bou Habib, Dumith Chequer ^c  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

AIDS; Dictyota pfaffii; Diterpenes; Dolabellane; HIV 1

Indexed keywords

DITERPENE; DOLABELLANE DITERPENE; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ALGA; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLANT GROWTH; TUMOR CELL; VIRUS INHIBITION; VIRUS REPLICATION;

ALGAE; ANTI-HIV AGENTS; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; PHYTOTHERAPY; PLANT EXTRACTS; VIRUS REPLICATION;

ALGAE; DICTYOTA PFAFFII; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33645531213     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-916209     Document Type: Article

References (25)

1. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17: 657-700
2. Peterlin BM, Trono D. Hide, shield and strike back: how HIV-infected cells avoid immune eradication. Nat Rev Immunol, 2003: 97-107
3. Stevenson M. HIV-1 pathogenesis. Nat Med 2003; 9: 853-60
4. Richman DD. HIV chemotherapy. Nature 2001; 410: 995-1001
5. Blankson JN, Persaud D, Siliciano R. The challenge of viral reservoir in HIV-1 infection. Annu Rev Med 2002; 53: 557-93
6. Condra JH, Miller MD, Hazuda DJ, Emini EA. Potential new therapies for the treatment of HIV-1 infection. Annu Rev Med 2002; 53: 541-55
7. Jung M, Lee S, Kim H. Recent studies on natural products as anti-HIV agents. Curr Med Chem 2000; 7: 649-61
8. Huang L, Chen CH. Molecular targets of anti-HIV-1 triterpenes. Curr Drug Targets Infect Disord 2002; 2: 33-6
9. Pereira HS, Leão-Ferreira LR, Moussatché N, Teixeira VL, Cavalcanti DN, Costa LJ et al. Antiviral activity of diterpenes isolated from the Brazilian marine alga Dictyota menstrualis against human immunodeficiency virus type 1 (HIV-1). Antiviral Res 2004; 64: 69-76
10. Aiken C, Chen CH. Betulinic acid derivatives as HIV-1 antivirals. Trends Mol Med 2005; 11: 31-6
11. Mengoni F, Lichtner M, Battinelli L, Marzi M, Mastroianni CM, Vullo V et al. In vitro anti-HIV activity of oleanolic acid on infected human mononuclear cells. Planta Med 2002; 68: 111-4
12. Xu HX, Zeng FQ, Wan M, Sim KY. Anti-HIV triterpene acids from Geum japonicum. J Nat Prod 1996; 59: 643-5
13. Barbosa JP, Pereira RC, Abrantes JL, Santos CCC, Rebello MA, Frugulhetti ICPP et al. Antiviral diterpenes from the Brazilian brown alga Dictyota pfaffii. Planta Med 2004; 70: 856-60
14. Verani A, Scarlatti G, Comar M, Tresoldi E, Polo S, Giacca M et al. C-C chemokines released by lipopolysaccharide (LPS)-stimulated human macrophages suppress HIV-1 infection in both macrophages and T cells. J Exp Med 1997; 185: 805-16
15. Hill CM, Deng H, Unutmaz D, Kewalramani VN, Bastiani L, Gorny MK et al. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. J Virol 1997; 71: 6296-304
16. Brazilian Network for HIV Isolation and Characterization. HIV-1 diversity in Brazil: genetic, biologic, and immunologic characterization of HIV-1 strains in thee potential HIV vaccine evaluation sites. J Acquir Immune Defic Syndr 2000; 23: 184-93
17. Ferraro GA, Mello MAG, Sutmoller F, Van Weyenberg J, Brazilian Network for HIV Isolation and Characterization, Shindo N et al. Biological characterization and chemokine receptor usage of HIV type 1 isolates prevalent in Brazil. AIDS Res Hum Retroviruses 2001; 17: 1241-7
18. Da Matta AD, Santos CVE, Pereira HS, Frugulhetti ICPP, Oliveira MRP, Souza MCBV et al. Synthesis of novel nucleosides of 4-oxoquinoline-3-carboxylic acid analogues. Heteroatom Chem 1999; 10: 197-202
19. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nozfziger TH et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988; 48: 4827-33
20. Bou-Habib DC, Gregory R, Oravecz T, Phillip WB, Lusso P, Norcross MA. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol 1994; 68: 6006-13
21. Siliciano JD, Siliciano RF. A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother 2004; 54: 6-9
22. De Clercq E. HIV inhibitors targeted at the reverse transcriptase. AIDS Res Hum Retroviruses 1992; 8: 119-34
23. Bell C, Matthews GV, Nelson MR. Non-nucleoside reverse transcriptase inhibitors - an overview. Int J STD AIDS 2003; 14: 71-7
24. Ninomya M, Matsuka S, Kawakubo A, Bito N. HIV-1 reverse transcriptase inhibitors containing hydroxydictyodial or dictyodial. Jpn Kokai Tokkyo Koho JP 1995; 285: 877
25. Schuitemaker H, Koot M, Kootstra NA, Derckensen MW, De Goede RE van Steenwijk RP et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992; 66: 1354-60